

# Eighteen months of teriparatide treatment leads to improvement of bone mineral density and trabecular bone score in patients with glucocorticoids induced osteoporosis: the results from prospective follow-up (registry OSTE0.sk)

## 18-mesačná liečba teriparatidom zlepšuje u pacientov s glukokortikoidmi indukovanou osteoporózou hodnoty hustoty kostného minerálu a trabekulárne kostné skóre: výsledky prospektívneho sledovania (register OSTE0.sk)

Juraj Payer<sup>1</sup>, Soňa Tomková<sup>2</sup>, Zdenko Killinger<sup>1</sup>, Kristína Brázdilová<sup>1</sup>, Peter Jackuliak<sup>1</sup>, Peter Vaňuga<sup>3</sup>, Alexandra Letkovská<sup>4</sup>, Pavol Masaryk<sup>4</sup>, Zlata Kmečová<sup>5</sup>, Martin Kužma<sup>1</sup>

<sup>1</sup>Comenius University Medical Faculty, 5<sup>th</sup> Department of Internal Medicine, University Hospital Bratislava, Slovakia

<sup>2</sup>Osteocentrum, Hospital Košice-Šaca, Košice, Slovakia

<sup>3</sup>National Institute of Endocrinology and Diabetology, Lubochňa, Slovakia

<sup>4</sup>National Institute of Rheumatic Diseases, Piešťany, Slovakia

<sup>5</sup>Osteocentrum of F.D. Roosevelt Faculty Hospital, Banská Bystrica, Slovakia

✉ **doc. MUDr. Martin Kužma, PhD.** | martin.kuzma@fmed.uniba.sk | kuzma@ru.unb.sk | www.uniba.sk

Received | Doručeno do redakcie | Doručené do redakcie 26. 10. 2018

Accepted | Prijato po recenzii | Prijaté po recenzii 28. 11. 2018

### Abstract

**Introduction:** Glucocorticoid therapy results in a rapid loss of bone mineral density (BMD) and glucocorticoid-induced osteoporosis (GIOP) is the most frequent and severe form of secondary osteoporosis. Teriparatide (TPTD) treatment of postmenopausal women with osteoporosis significantly increases cancellous bone volume and connectivity, improves trabecular morphology with a shift toward a more plate-like structure, and increases cortical bone thickness. **Aim of the study:** Assessment of change in BMD and trabecular bone score (TBS) after 12- and 18-months treatment with TPTD in patients with GIOP. **Patients and methods:** Prospective multicentric, non-controlled follow-up of the effect and safety of TPTD treatment in patients with GIOP, performed in 5-referral centers specified at the treatment with TPTD. In all patients included in OSTE0.sk registry the measurements of BMD, at lumbar spine (LS) and proximal femur, and bone turnover markers were performed periodically. In the subset of participants, a TBS was measured. **Results:** From total number of 263 patients included in the registry, 129 patients (20 men aged 51,5 years/109 women aged 59,7 years) were included in the final analysis. An increase of lumbar spine (LS) BMD at month 12 (+8.3%,  $p < 0.001$ ) and at month 18 an increase of total hip (+3.85%,  $p < 0.001$ ), femoral neck (+3.26 %,  $p < 0.001$ ) and LS BMD (+9.28%,  $p < 0.001$ ) in comparison to baseline values after treatment with TPTD were observed. In the subset ( $n=12$ ), TBS increase of 2,4% ( $p=0,01$ ) during first 12 months. 18 months of TPTD therapy led to significant increase of bone turnover markers. **Conclusion:** 18 month treatment with TPTD led to significant increase of BMD with concomitant increase in all assessed bone turnover markers. In addition,

in subset of the study group and increase of TBS after 12 months was observed. According to these results, it has been proven that TPTD is highly effective osteoanabolic drug in patients with GIOP.

**Key words:** bone mineral density (BMD) – glucocorticoid-induced osteoporosis – TBS – teriparatide

### Abstrakt

**Úvod:** Liečba glukokortikoidmi má za následok rýchlu stratu denzity kostného minerálu (BMD) a glukokortikoidmi indukovaná osteoporóza (GIOP) je najčastejšou a závažnou formou sekundárnej osteoporózy. Liečba žien s postmenopauzálnou osteoporózou teriparatidom (TPTD) významne zvyšuje trabekulárny kostný objem a konektivitu, zlepšuje trabekulárnu morfológiu s posunom smerom k viac doštičkovitej štruktúre a zvyšuje hrúbku kortikálnej kosti. **Ciel štúdie:** Posúdení zmeny BMD a trabekulárneho kostného skóre (TBS) po 12- a 18-mesačnej liečbe TPTD u pacientov s GIOP. **Pacienti a metódy:** Prospektívne multicentrické, nekontrolované sledovanie účinnosti a bezpečnosti liečby TPTD u pacientov s GIOP, uskutočňované v 5 špecializovaných centrách ustanovených pre liečbu TPTD. U všetkých pacientov zaradených do registru OSTEO.sk bolo pravidelne uskutočňované meranie BMD v bedrovej chrbtici a proximálnom femoru a sledovanie markerov kostného obratu. V podskupine účastníkov bolo merané TBS. **Výsledky:** Z celkového počtu 263 pacientov zaradených do registra bolo do záverečnej analýzy zahrnutých 129 pacientov (20 mužov vo veku 51,5 let/109 žien vo veku 59,7 let). Po liečbe TPTD bol zistený v porovnaní s východiskovými hodnotami nárast BMD v bedrovej chrbtici v 12. mesiaci (+ 8,3 %,  $p < 0,001$ ) a v 18. mesiaci nárast BMD hlavica femoru (+ 3,85 %,  $p < 0,001$ ), krčku femoru (+ 3,26 %,  $p < 0,001$ ) a bedrovej chrbtice (+ 9,28 %,  $p < 0,001$ ). V podskupine ( $n = 12$ ) v priebehu prvých 12 mesiacov narástlo TBS o 2,4 % ( $p = 0,01$ ). 18-mesačná liečba TPTD viedla k významnému zvýšeniu markerov kostného obratu. **Záver:** 18-mesačná liečba TPTD viedla k významnému zvýšeniu BMD so súčasným zvýšením všetkých hodnotených markerov kostného obratu. Okrem toho bolo v podskupine účastníkov štúdie pozorované zvýšenie TBS po 12 mesiacoch liečby. Podľa týchto výsledkov bolo preukázané, že u pacientov s GIOP je TPTD vysoko účinný osteoanabolický liek.

**Kľúčové slová:** kostná minerálna denzita (BMD) – osteoporóza indukovaná glukokortikoidmi (GIOP) – trabekulárne kostné skóre (TBS) – teriparatide

## Introduction

The prevalence of oral glucocorticoid (GC) use is 0.9% of the total adult population rising to 2.5% at age over 70 years [1]. GC therapy results in a rapid bone loss within the first weeks of treatment leading to osteoporotic fractures in 3 to 6 months from the beginning of GC treatment [2].

Histomorphometric analysis of biopsies from GC-treated individuals have demonstrated a reduction in bone formation at the cellular and tissue level, resulting in reduced bone volume and trabecular thickness. Higher doses and the long-term use of GC, however, also may be associated with an increase in bone resorption, leading to greater bone loss and disruption of cancellous bone architecture [3–7]. GC therapy is associated with reduced intestinal and renal calcium absorption and increased urinary calcium excretion, therefore increasing calcium intake seems to be a logical approach to slow decrease in bone mass and microarchitecture [8,9].

Teriparatide (TPTD) increases periosteal and endocortical bone formation – total bone area, cortical area and bone strength. TPTD treatment of postmenopausal women with osteoporosis significantly increases cancellous bone volume and connectivity, improves trabecular morphology with a shift toward a more plate-

like structure, and increases cortical bone thickness, leading to reducing in vertebral and non-vertebral fracture risk [2,10–17].

In last years, a trabecular bone score (TBS), indirect non-invasive bone parameter to describe degradation of trabecular microstructure is widely used [18] And high TBS value indicates better whereas lower TBS indicates worse trabecular bone structure and meaning greater risk of osteoporosis fractures [19–22]. There are several studies proving positive effect of TPTD on TBS in comparison or following to bisphosphonate treatment in patients with GC-induced osteoporosis (GIOP) [23–25].

This study was aimed to assess changes in bone mineral density (BMD) and TBS after 18-month period of treatment with TPTD in patients with GIOP concentrated into referral TPTD treatment centers in Slovakia.

## Patients and methods

### Patients

From January 2010 till January 2014, a prospective follow-up on effect and safety of TPTD treatment in GIOP patients in 5 referral centers specified at the treatment with TPTD, was performed.

**The patients inclusion criteria were as follows:**

1. bone mineral density T-score < -2.9 or one or more osteoporotic fractures
2. the use > 5 mg corticoids for more than 3 months

The regional medical ethical committees in each centre gave approval for the study

**Treatment**

All patients were treated with 20 µg of recombinant humane parathyroid hormone [1–34] – teriparatide (Forsteo®, Eli Lilly and Company, Netherlands BV), administered daily, subcutaneously. All patients enrolled in the study received daily supplements of 500 to 1 000 mg of Calcium and 400 to 800 IU of Vitamin D.

**Outcome measures**

The primary outcomes were defined as change in bone mineral density (BMD) at femoral neck (FN), total hip (TH) and lumbar spine (LS) and bone turnover markers after 12 and 18 months of TPTD treatment. Secondary outcomes included prevalence of clinical fractures, changes in TBS, tolerability and safety of the treatment. It was the prospective, open label, non-randomized, 18-months study in five centers in Slovakia (January 2010 – January 2014).


**Methods**

In all patients, LS BMD, FN and TH region was measured at the baseline, month 12 and 18 using dual-energy X-ray absorptiometry (Hologic Discovery). In all five centers

**Table 1 | Baseline characteristics of the study sample**

parameter (unit)	all (N=129)	men (N=20)	women (N=109)	difference men vs women (p-value)
age (years)	57.3 ± 12.1	51.5 ± 13.7	59.7 ± 14.8	p = 0.05
weight (kg)	74.6 ± 5.6	84.3 ± 3.5	72.1 ± 4.8	< 0.001
height (cm)	168.1 ± 8.1	173.2 ± 6.1	155.1 ± 4.4	< 0.001
mean dose of GC (mg/day)	10.9 ± 9	13.6 ± 11.3	10.9 ± 8.5	NS
duration of GC-treatment (months)	120 ± 106	97 ± 112	124 ± 105	NS

\*values are expressed as mean ±SD (Standard Deviation)

**Figure 1 | Doses of glucocorticoids in the study group at the beginning of the follow-up**

<sup>1</sup>Patients with complete information SD – Standard Deviation

Hologic densitometer (Discovery) with identical software and normative database was used.


All patients were assessed for serum levels of procollagen type 1, aminoterminal propeptide (P1NP),  $\beta$ -crosslaps (CTX) and osteocalcin (OC) at month 0, 6, 12 and 18. the same method (ECLIA) and Ca in routine manner by local laboratories.

TBS derived from lumbar spine DXA was assessed by the iN Sight® v. 1.0 (Medimaps, France) in the subset of patients.

**Statistics**


Standard descriptive parametric and nonparametric statistics were used for the description of the data. Continuous variables were described using mean and standard deviation or median supplemented by 5<sup>th</sup> and 95<sup>th</sup> percentile; categorical variables were described using absolute and relative frequencies of categories (percentage). Statistical significance of time related changes in pair-wise comparisons was analyzed using pair-wise t-test or Wilcoxon paired test for detailed comparisons of

**Figure 2 | Percentage of patients with fractures (vertebral and non-vertebral) before start of the treatment in study population**



<sup>†</sup>Patients with complete information SD – Standard Deviation

**Figure 3 | Changes in BMD over time periods. Treatment with TPTD led to an increase in BMD of total hip, femoral neck and LS assessed by means of BMD at month 12 and 18**



two time points. The results were considered statistically significant at the level of  $\alpha < 0.05$  in all applied analyses. Analyses were performed using IBM SPSS 22.0.0 (IBM Corporation, 2013).

## Results

From total of 263 GIOP patients on TPTD treatment a number of 129 patients (20 men/109 women), who properly terminated TPTD treatment after 18 months, were included in the study. **Figure 1** and **Figure 2** shows


doses of GC used by patient and number of all fractures at the beginning of the follow-up. Baseline characteristics are in **Table 1**.

### Change in bone mineral density


After TPTD treatment, an increase of lumbar spine (LS) BMD at month 12 (+8.3%,  $p < 0.001$ ) and total hip (+3.85%,  $p < 0.001$ ), femoral neck (+3.26 %,  $p < 0.001$ ) and LS BMD (+9.28%,  $p < 0.001$ ) at month 18 was observed (**Figure 3**).

**Figure 4 | Changes in bone turnover markers after TPTD treatment. Treatment led to significant increase in all three evaluated bone turnover markers**


#### 4.1



#### 4.2



#### 4.3



M – month P1NP – procollagen type 1 amino-terminal propeptide sCTX – serum C-terminal telopeptide

### Change in bone turnover markers

During study period, P1NP increase of 233%; 304.5% and 176.3% at month 6; 12 and 18 (all  $p < 0.001$ ), respectively, see **Figure 4** for further details.

CTx increased of 171.8% ( $p < 0.001$ ); 196.9% ( $p < 0.001$ ) and 154.8% ( $p < 0.001$ ) at month 6, 12 and 18, respectively. Similarly, OC increased of 248% ( $p < 0.001$ ); 225.3% ( $p < 0.001$ ) and 178.3% ( $p < 0.001$ ) at month 6, 12 and 18, respectively.

Serum calcium levels above reference range (2.7 mmol/l) were present in 3,2%; 8,6%; 5,8% and 3,4% of patients at the baseline, month 6, 12 and 18, respectively (**Figure 5**).

### Effect on fractures

After 18 months of treatment a decrease in number of new onset fractures (2 high trauma, 1 low trauma wrist fracture) was observed compared to the baseline (6 high trauma, 0 low trauma fractures), **Table 2**.

Treatment with TPTD was well tolerated and no serious side effects were observed.



### Effect on trabecular bone score

TBS was evaluated in the subset of 12 patients (7 women, 5 males). An increase 2,4% ( $p = 0,01$ ) of TBS was observed at month 12 of TPTD treatment (**Figure 6**).

### Discussion

The beneficial effects of daily injection of TPTD have been shown in several randomized, placebo-controlled trials with glucocorticoid-induced osteoporosis [2,15–17].

In this study, an effect of osteoanabolic treatment with TPTD on BMD, bone turnover markers and TBS



**Table 2 | The number of new onset fractures in the study group in each time period**

time	number of patients	total number of fractures	high-trauma	low-trauma
6 months	4	6	6	0
12 months	1	1	1	0
18 months	3	3	2	1

was evaluated. Daily TPTD administration for the period of 18 months had positive effect on BMD and bone formation as documented by increase of bone turnover markers. In addition, in the small subset, 12 month treatment resulted in increase of TBS. In past years, there were several studies concerning the effect of TPTD on BMD and the risk of osteoporotic fractures. In the randomized, double-blind clinical trial of 36 months effect of TPTD in comparison to daily alendronate administration in GIOP patients showed significant skeletal benefits (documented by increase in BMD) in patients with GIOP, compared to alendronate [26–28]. Although, our analysis was limited because of absence of control group, the effect of TPTD on BMD was obvious, preferably after 18 months of treatment. The effect of TPTD was supported by increase of bone turnover markers followed with slight decrease at month 18. In other trials comparing a bisphosphonate with TPTD in severe postmenopausal osteoporosis, TPTD therapy was associated with increased areal and volumetric BMD and bone strength compared to alendronate [28,29]. This response may reflect the characteristic ability of glucocorticoids to inhibit osteoblast and osteocyte function profoundly by several mechanisms, including the stimulation of apoptosis [30]. Interestingly, Reid et al. in two of the previous studies with TPTD documented a reduction in non-vertebral fractures in postmenopausal women with osteoporosis [31,32]. Another study documented in a group of postmenopausal women with prevalent vertebral fracture a significant decrease in risk of vertebral and non-vertebral fractures after 18-month administration. The treatment was associated with significant improvement in quality of life [33].

Our study, however not aimed to evaluate incidence of fractures, supports the finding with a decreasing number of newly developed high trauma fractures (despite the 1 new low trauma fracture). The standard of care for patients at risk for glucocorticoid-associated bone loss and osteoporosis includes a choice of antiresorptive agents. However, for patients with established osteoporosis who are at high risk for fracture, more effective therapy may be warranted [30,34–39]. In 18-month trial in men with glucocorticoid-induced osteoporosis, TPTD showed also larger improvements in spinal BMD and bone strength and microstructure than risendronate [40]. This is also supported by the effect of TPTD on TBS in our study.

## Conclusion

According to the previous studies TPTD as the anabolic agent is appropriate therapeutic strategy for patients at high risk for fracture, such as patients on GC treatment. In this study, treatment with TPTD resulted in BMD in-

crease followed by significant changes in bone turnover markers. The effect of TPTD on bone structure was additionally documented by its positive effect on TBS. However, larger studies to evaluate TBS are needed. According to these findings, TPTD is highly effective osteoanabolic drug in patients with GIOP.

## Acknowledgments

The authors confirm that all the research meets the ethical guidelines, including adherence to the legal requirements of Slovakia. We assert that there are no conflicts of interest (both personal and institutional) regarding specific financial interests that are relevant to the work conducted or reported in this manuscript.

## References

1. Van Staa TP, Leufkens HG, Cooper C. The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis. *Osteoporos Int* 2002; 13(10): 777–787. Dostupné z DOI: <<http://dx.doi.org/10.1007/s001980200108>>.
2. Payer J, Brazdilova K, Jackuliak P. Management of glucocorticoid-induced osteoporosis: prevalence, and emerging treatment options. *Drug Healthc Patient Saf* 2010; 2: 49–59.
3. Dale Carbonare L, Arlot ME, Chavassieux PM et al. Comparison of trabecular bone microarchitecture and remodeling in glucocorticoid-induced and postmenopausal osteoporosis. *J Bone Miner Res* 2001; 16(1): 97–103. Dostupné z DOI: <<http://dx.doi.org/10.1359/jbmr.2001.16.1.97>>.
4. Van Staa TP, Leufkens HGM, Abenhaim L et al. Oral corticosteroids and fracture risk: relationship to daily and cumulative doses. *Rheumatology* 2000; 39(12): 1383–1389.
5. Van Staa T, Leufkens HGM, Abenhaim L et al. Use of oral corticosteroids and risk of fractures. *J Bone Miner Res*. 2000; 15(6): 993–1000. Dostupné z DOI: <<http://dx.doi.org/10.1359/jbmr.2000.15.6.993>>.
6. De Gregório LH, Lacativa PG, Melazzi AC et al. Glucocorticoid-induced osteoporosis. *Arq Bras Endocrinol Metabol* 2006; 50(4): 793–801.
7. Van Staa TP. The pathogenesis, epidemiology and management of glucocorticoid-induced osteoporosis. *Calcif Tissue Int* 2006; 79(3): 129–137. Dostupné z DOI: <<http://dx.doi.org/10.1007/s00223-006-0019-1>>.
8. Migliaccio S, Brama M, Malavolta N. Management of glucocorticoid-induced osteoporosis: role of teriparatide. *Ther Clin Risk Manag* 2009; 5(2): 305–310.
9. Lekamwasam S, Adachi JD, Agnusdei D et al. A framework for the development of guidelines for the management of glucocorticoid-induced osteoporosis. *Osteoporos Int* 2012; 23(9): 2257–2276. Dostupné z DOI: <<http://dx.doi.org/10.1007/s00198-012-1958-1>>.
10. Jiang Y, Zhao JJ, Mitlak BH et al. Recombinant human parathyroid hormone (1–34) [teriparatide] improves both cortical and cancellous bone structure. *J Bone Miner Res* 2003; 18(11): 1932–1941. Dostupné z DOI: <<http://dx.doi.org/10.1359/jbmr.2003.18.11.1932>>.
11. Neer RM, Arnaud CD, Zanchetta JR et al. Effect of parathyroid hormone (1–34) on fractures and bone mineral density in postmenopausal women with osteoporosis. *N Engl J Med* 2001; 344(19): 1434–1441. Dostupné z DOI: <<http://dx.doi.org/10.1056/NEJM200105103441904>>.
12. Rizzoli R, Adachi JD, Cooper C et al. Management of glucocorticoid-induced osteoporosis. *Calcif Tissue Int* 2012; 91(4): 225–243. <<http://dx.doi.org/10.1007/s00223-012-9630-5>>.
13. Uihlein AV, Leder BZ. Anabolic therapies for osteoporosis. *Endocrinol Metab Clin North Am* 2012; 41(3): 507–525. Dostupné z DOI: <<http://dx.doi.org/10.1016/j.ecl.2012.05.002>>.
14. Vanuga P, Tomkova S, Masaryk P et al. Slovak register of patient with severe osteoporosis on osteoanabolic treatment. *Osteoporos Int* 2012; 23(Suppl 2): S239–S240.

15. Bultink IE, Baden M, Lems WF. Glucocorticoid-induced osteoporosis: an update on current pharmacotherapy and future directions. *Expert Opin Pharmacother* 2013;14(2):185–97. Dostupné z DOI: <<http://dx.doi.org/10.1517/14656566.2013.761975>>.
16. Amiche MA, Albaum JM, Tadrous M et al. Efficacy of osteoporosis pharmacotherapies in preventing fracture among oral glucocorticoid users: a network meta-analysis. *Osteoporos Int* 2016; 27(6): 1989–1998. Dostupné z DOI: <<http://dx.doi.org/10.1007/s00198-015-3476-4>>.
17. Blick SK, Dhillon S, Keam SJ. Teriparatide: a review of its use in osteoporosis. *Drugs* 2008; 68(18): 2709–2737. Dostupné z DOI: <<http://dx.doi.org/10.2165/0003495-200868180-00012>>.
18. Pothuau L, Carceller P, Hans D. Correlations between grey-level variations in 2D projection images (TBS) and 3D microarchitecture: applications in the study of human trabecular bone microarchitecture. *Bone* 2008; 42(4): 775–787. Dostupné z DOI: <<http://dx.doi.org/10.1016/j.bone.2007.11.018>>.
19. Hans D, Goertzen AL, Krieg MA et al. Bone microarchitecture assessed by TBS predicts osteoporotic fractures independent of bone density: the Manitoba study. *J Bone Miner Res* 2011; 26(11): 2762–2769. Dostupné z DOI: <<http://dx.doi.org/10.1002/jbmr.499>>.
20. Briot K, Paternotte S, Kolta S et al. Added value of trabecular bone score to bone mineral density for prediction of osteoporotic fractures in postmenopausal women: the OPUS study. *Bone* 2013; 57(1): 232–236. Dostupné z DOI: <<http://dx.doi.org/10.1016/j.bone.2013.07.040>>.
21. Boutroy S, Hans D, Sornay-Rendu E et al. Trabecular bone score improves fracture risk prediction in non-osteoporotic women: the OFELY study. *Osteoporos Int* 2013; 24(1): 77–85. Dostupné z DOI: <<http://dx.doi.org/10.1007/s00198-012-2188-2>>.
22. Iki M, Tamaki J, Kadowaki E et al. Trabecular bone score (TBS) predicts vertebral fractures in Japanese women over 10 years independently of bone density and prevalent vertebral deformity: the Japanese Population-Based Osteoporosis (JPOS) cohort study. *J Bone Miner Res* 2014; 29(2): 399–407. Dostupné z DOI: <<http://dx.doi.org/10.1002/jbmr.2048>>.
23. Senn C, Gunther B, Popp AW et al. Comparative effects of teriparatide and ibandronate on spine bone mineral density (BMD) and microarchitecture (TBS) in postmenopausal women with osteoporosis: a 2-year open-label study. *Osteoporos Int* 2014; 25(7): 1945–1951. Dostupné z DOI: <<http://dx.doi.org/10.1007/s00198-014-2703-8>>.
24. Saag KG, Agnusdei D, Hans D et al. Trabecular Bone Score in Patients With Chronic Glucocorticoid Therapy-Induced Osteoporosis Treated With Alendronate or Teriparatide. *Arthritis Rheumatol* 2016; 68(9): 2122–2128. Dostupné z DOI: <<http://dx.doi.org/10.1002/art.39726>>.
25. Miyaoka D, Imanishi Y, Ohara M et al. Effects of Teriparatide and Sequential Minodronate on Lumbar Spine. *Bone Mineral Density and Microarchitecture in Osteoporosis*. *Calcif Tissue Int* 2017; 101(4): 396–403. Dostupné z DOI: <<http://dx.doi.org/10.1007/s00223-017-0295-y>>.
26. Saag KG, Zanchetta JR, Devogelaer JP et al. Effects of teriparatide versus alendronate for treating of glucocorticoid-induced osteoporosis: thirty-six-month results of a randomized, double-blind, controlled trial. *Arthritis Rheum* 2009; 60(11): 3346–3355. Dostupné z DOI: <<http://dx.doi.org/10.1002/art.24879>>.
27. Saag KG, Shane E, Boonen S et al. Teriparatide or alendronate in glucocorticoid-induced osteoporosis. *N Engl J Med* 2007; 357(20): 2028–2039. Dostupné z DOI: <<http://dx.doi.org/10.1056/NEJMoa071408>>.
28. McClung MR, San Martin J, Miller PD et al. Opposite bone remodeling effects of teriparatide and alendronate in increasing bone mass. *Arch Intern Med* 2005; 165(15): 1762–1768. Dostupné z DOI: <<http://dx.doi.org/10.1001/archinte.165.15.1762>>.
29. Keaveny TM, Donley DW, Hoffmann PF et al. Effects of teriparatide and alendronate on vertebral strength as assessed by finite element modeling of QCT scans in women with osteoporosis. *J Bone Miner Res* 2007; 22(1): 149–157. Dostupné z DOI: <<http://dx.doi.org/10.1359/jbmr.061011>>.
30. O'Brien CA, Jia D, Plotkin LI et al. Glucocorticoids act directly on osteoblasts and osteocytes to induce their apoptosis and reduce bone formation and strength. *Endocrinology* 2004; 145(4): 1835–1841. <<http://dx.doi.org/10.1210/en.2003-0990>>.
31. Reid DM, Hughes RA, Laan RF et al. Efficacy and safety of daily risedronate in the treatment of corticosteroid-induced osteoporosis in men and women: a randomized trial. *J Bone Miner Res* 2000; 15(6): 1006–1013. Dostupné z DOI: <<http://dx.doi.org/10.1359/jbmr.2000.15.6.1006>>.
32. Reid DM, Adami S, Devogelaer JP et al. Risedronate increases bone density and reduces vertebral fracture risk within one year in men on corticosteroid therapy. *Calcif Tissue Int* 2001; 69(4): 242–247.
33. Neer RM, Claude DA, Jose RZ et al. Effect of Parathyroid hormone (1–34) on fractures and bone mineral density in postmenopausal women with osteoporosis. *N Engl J Med* 2001; 344(19): 1434–1441. Dostupné z DOI: <<http://dx.doi.org/10.1056/NEJM200105103441904>>.
34. Adachi JD, Saag KG, Delmas PD et al. Two-year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids: a randomized double-blind, placebo-controlled extension trial. *Arthritis Rheum* 2001; 44(1): 202–211. Dostupné z DOI: <[http://dx.doi.org/10.1002/1529-0131\(200101\)44:1<202::AID-ANR27>3.0.CO;2-W](http://dx.doi.org/10.1002/1529-0131(200101)44:1<202::AID-ANR27>3.0.CO;2-W)>.
35. Sambrook PN, Kotowicz M, Nash P et al. Prevention and treatment of glucocorticoid-induced osteoporosis: a comparison of calcitriol, vitamin D plus calcium, and alendronate plus calcium. *J Bone Miner Res* 2003; 18(5): 919–924. Dostupné z DOI: <<http://dx.doi.org/10.1359/jbmr.2003.18.5.919>>.
36. Wallach S, Cohen S, Reid DM et al. Effects of risedronate treatment on bone density and vertebral fracture in patients on corticosteroid therapy. *Calcif Tissue Int* 2000; 67(4): 277–285.
37. Neer RM, Arnaud CD, Zanchetta JR et al. Effect of parathyroid hormone (1–34) on fractures and bone mineral density in postmenopausal women with osteoporosis. *N Engl J Med* 2001; 344(9): 1434–1441. Dostupné z DOI: <<http://dx.doi.org/10.1056/NEJM200105103441904>>.
38. Murphy DR, Smolen LJ, Klein TM et al. The cost effectiveness of teriparatide as a first-line treatment for glucocorticoid-induced and postmenopausal osteoporosis patients in Sweden. *BMC Musculoskelet Disord* 2012; 13: 213. Dostupné z DOI: <<http://dx.doi.org/10.1186/1471-2474-13-213>>.
39. Bultink IEM, Baden M, Lems WF. Glucocorticoid-induced osteoporosis: An update on current pharmacotherapy and future directions. *Expert Opin Pharmacother* 2013; 14(2): 185–197. Dostupné z DOI: <<http://dx.doi.org/10.1517/14656566.2013.761975>>.
40. Gluer CC, Marin F, Ringe JD et al. Comparative effects of teriparatide and risedronate in glucocorticoid-induced osteoporosis in men: 18-month results of the EuroGIOPs trial. *J Rheumatol* 2012; 39(3): 600–609.